Nicox reported cash and cash equivalents of 32.6 million euros at the end of the second quarter of 2018, down from 36.3 million euros in the first quarter, according to a company press release.
Net revenue for the quarter was 0.226 million euros, entirely comprised of royalties from sales of Vyzulta by global partner Bausch + Lomb. In the same quarter of 2017, Nicox recorded no revenue.
A research agreement with Ironwood Pharmaceuticals was announced in June, in which the two companies will work together to generate novel compounds intended (Read more...)
Uncategorized